Biotech chameleons: Quark Pharma aims for $81M IPO
(UPDATED: See below.)
For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes just to be whatever faddish investors want them to be.
Today, for… Continue Reading
Bioscrypt acquires 3D facial recognition co., A4Vison, and gets more cash
Toronto, Canada’s Bioscrypt, a provider of technologies that help companies control access to their facilities, said it will acquire A4Vision, the Sunnyvale, Calif. provider of 3D facial imaging and recognition technology.
Concurrent with the completion of the merger, institutional investors associated with A4Vision have agreed… Continue Reading
Theranos raises $28.5M for device tracking effects of drugs on patients
Theranos, a Menlo Park company developing devices that enable healthcare professionals and pharmaceutical companies to track patients’ responses to drugs, has raised $28.5 million of a $30 million planned third round, according to a filing with the Securities and Exchange Commission cited by VentureWire (sub… Continue Reading